Arkansas 2025 Regular Session

Arkansas House Bill HB1619

Introduced
2/27/25  
Refer
2/27/25  
Report Pass
3/18/25  
Engrossed
3/19/25  
Refer
3/19/25  
Report Pass
4/7/25  
Enrolled
4/10/25  
Chaptered
4/16/25  

Caption

To Set Administration Fees Under The Arkansas Medicaid Program For Immunizations And Monoclonal Antibodies For Respiratory Syncytial Virus Disease; And To Provide Civil Immunity.

Impact

The passage of HB1619 would have a significant impact on state laws concerning healthcare administration and Medicaid reimbursements. By standardizing the fees for these specific immunizations and treatments, Arkansas aims to increase access to vital healthcare services, particularly for vulnerable populations such as young children. Furthermore, the introduction of civil immunity provisions is designed to encourage healthcare providers to offer these services without the fear of potential legal repercussions, provided they adhere to the standards of care. This aspect of the bill could enhance participation among providers, ultimately benefiting patient care and public health outcomes.

Summary

House Bill 1619 is a legislative proposal aimed at addressing the management of immunizations and monoclonal antibodies for respiratory syncytial virus (RSV) disease within the Arkansas Medicaid program. The bill sets forth provisions to reimburse administration fees that align with the maximum administration fee prescribed in the state's Vaccines for Children Program. The essence of this measure is to ensure that infants and toddlers receive the necessary immunizations for RSV without creating additional financial burdens on healthcare providers.

Sentiment

Broadly, the sentiment surrounding HB1619 appears to be positive, particularly among health advocates who recognize the importance of facilitating access to critical healthcare for infants and toddlers. Supporters of the bill emphasize the necessity of combatting RSV among young children, which can lead to severe respiratory complications. However, there could be some contention over the implications of civil immunity, with critics possibly raising concerns about the potential for reduced accountability among providers in rare cases of negligence.

Contention

Notable points of contention revolve around the civil immunity clause. While this provision serves to protect healthcare providers from liability, it raises questions about maintaining high standards of care in medical practices. Opponents may argue that such immunity could inadvertently allow for lapses in patient care, which could harm infants if negligence occurs. Additionally, discussions may arise regarding the appropriateness of government setting such standardized fees and how these measures may affect the overall healthcare landscape in Arkansas.

Companion Bills

No companion bills found.

Similar Bills

MI SR0050

A resolution to urge the Centers for Disease Control and Prevention to include new respiratory syncytial virus immunization technologies (including vaccines and monoclonal antibodies) within the federal Vaccines for Children Program.

AR HB1052

To Mandate Coverage For Certain Respiratory Syncytial Virus Disease Immunization Technologies For Certain Individuals.

LA SR101

Urges and requests the Centers for Disease Control and Prevention to include monoclonal antibodies for RSV within the federal Vaccines for Children program.

IL SR0136

RSV VACCINE-CDC

IL HR0163

RSV VACCINE-CDC

LA SB550

Provides exemption from local sales taxes for certain complex biologics used by a patient in his medical treatment. (7/1/12)

GA SR304

RSV Immunization Technologies; vaccines and monoclonal antibodies within the federal VFC program; support the inclusion

GA HR531

Federal VFC program; inclusion of new RSV immunization technologies, including vaccines and monoclonal antibodies; commend